ClinicalTrials.Veeva

Menu

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

M

Myrexis

Status and phase

Completed
Phase 1

Conditions

Refractory Solid Tumors

Treatments

Drug: MPC-6827

Study type

Interventional

Funder types

Industry

Identifiers

NCT00394446
MPC6827-04-001

Details and patient eligibility

About

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Enrollment

48 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Advanced or Metastatic Cancer
  2. Measurable / Evaluable Disease
  3. Karnofsky score greater than or equal to 70%
  4. Adequate Hematology / Organ function
  5. No Baseline peripheral or central neuropathy above grade 1

Exclusion criteria

  1. Hypersensitivity to Cremophor EL
  2. Pregnant or Lactating
  3. Spinal Cord Compression
  4. Pre-existing Dementia / Cognitive Disfunction
  5. Require Neupogen or Neulasta to Maintain Neutrophil Count
  6. Have Primary Brain Cancer
  7. Have history of Ischemic Heart Disease
  8. Have Diabetes

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems